UNSPSC 51433406: Diproteverine hydrochloride

This classification denotes a calcium channel blocker with the molecular formula C26H35NO4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T587ZFV6UM, chemically known as 1-(3,4-diethoxybenzyl)-3,4-dihydro-6,7-diisopropoxyisoquinoline but more generally known as diproteverine hydrochloride, which bears US NIH Compound Identifier 50463. Most nations, for tariff and trade purposes, schedule diproteverine hydrochloride under HS 29391900. As of Q4 2014, DIPROTEVERINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity.

Diproteverine hydrochloride bears US NLM identifiers UMLS ID C0107185 and NCI Concept Code C97979. SMILES: CCOC1CCC(CC1OCC)CC2=NCCC3C2CC(C(C3)OC(C)C)OC(C)C.CL.

UNSPSC 51433406 Diproteverine hydrochloride is a Commodity code tracking pharmaceutical supply procurement by state and local governments, though the recent opportunities block shows minimal direct sourcing of this specific agent and instead reflects broader emergency medicine and pharmacy benefit management solicitations where such products may be included. State and local governments buying under this code procure advanced life support medications and generic pharmaceuticals through direct manufacturers, cooperative purchasing vehicles, and emergency services supply chains. Issuing bodies span municipal fire departments procuring emergency medications, state health and human services agencies managing pharmacy benefit programs, and multistate cooperative purchasing alliances sourcing generic pharmaceuticals for distributed state and local facilities. The City of Tampa's Purchasing Department and the Texas Health and Human Services Commission represent the primary recent buyers, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) operating as an intermediary aggregating demand across multiple participating jurisdictions.

Recent activity concentrates in Florida and Texas. The City of Tampa's sealed-bid solicitation (26P00188, posted April 24, 2026, due April 8, 2026) sought Advanced Life Support Medications including labetalol, epinephrine, adenosine, and diltiazem for Tampa Fire Rescue, with an estimated contract value of $40,000 and a one-year term plus optional renewals. The Texas Health and Human Services Commission issued an RFI (HHS0017013, April 3, 2026) exploring direct-to-manufacturer prescription fulfillment models outside traditional PBM and wholesaler channels. MMCAP's RFP (S1070000015802, due March 26, 2026) established multi-award contracts for generic pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson across Minnesota, Oregon, and other participating jurisdictions, with pricing weighted heavily on competitiveness (75 percent) and contract effectiveness July 1, 2026. Diproteverine hydrochloride itself does not appear explicitly in the recent blocks; activity under the broader code focuses on emergency medications and generic pharmaceutical procurement rather than this specific agent.